Charlottesville, VA – HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda.
/PRNewswire/ OpenBench, Inc., a pioneer in success-driven hit discovery partnerships, has agreed to assign ownership of two promising chemical series to.
/PRNewswire/ HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare metabolic disorders, has appointed Patrick Horn,.